Biogen and Samsung Bioepis have agreed a licensing deal with AbbVie that clears the way for their new biosimilar therapy Imraldi to be launched in Europe.

Under the terms of the agreement, AbbVie will grant patent licences for the use and sale of Imraldi in Europe on a country-by-country basis, with Biogen and Samsung Bioepis making royalty payments. This brings an end to a patent dispute over the adalimumab biosimilar.

“Biogen and Samsung Bioepis have agreed a deal with AbbVie that ends a legal dispute over the sale of the biosimilar product Imraldi in Europe.“

Imraldi is based on AbbVie's blockbuster drug Humira and is an anti-TNF therapy designed for the treatment of various forms of arthritis, as well as plaque psoriasis, Crohn's disease, ulcerative colitis and non-infectious uveitis.

Biogen expects to launch the drug in Europe later this year, with the launch complementing its existing portfolio of anti-TNF therapies, including Benepali and Flixabi.

Ian Henshaw, global head of biosimilars at Biogen, said: "Biogen already markets two biosimilars in Europe and the planned introduction of Imraldi on October 16th could potentially expand patient choice by offering physicians more options to meet the needs of patients, while delivering significant savings to healthcare systems."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.